PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
8.64%
Revenue growth 50-75% of VET's 13.46%. Martin Whitman would scrutinize if slower growth is temporary.
3.30%
Cost growth less than half of VET's 12.60%. David Dodd would verify if cost advantage is structural.
13.14%
Similar gross profit growth to VET's 14.07%. Walter Schloss would investigate industry dynamics.
4.15%
Margin expansion exceeding 1.5x VET's 0.54%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-1.19%
G&A reduction while VET shows 16.11% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
22.52%
Other expenses growth above 1.5x VET's 4.40%. Michael Burry would check for concerning trends.
20.84%
Operating expenses growth above 1.5x VET's 6.28%. Michael Burry would check for inefficiency.
12.81%
Total costs growth 1.25-1.5x VET's 9.42%. Martin Whitman would scrutinize control.
-8.49%
Interest expense reduction while VET shows 37.61% growth. Joel Greenblatt would examine advantage.
1.68%
D&A growth less than half of VET's 7.91%. David Dodd would verify if efficiency is sustainable.
-36.58%
EBITDA decline while VET shows 133.04% growth. Joel Greenblatt would examine position.
-41.62%
EBITDA margin decline while VET shows 105.40% growth. Joel Greenblatt would examine position.
-4550.00%
Operating income decline while VET shows 34.48% growth. Joel Greenblatt would examine position.
-4196.17%
Operating margin decline while VET shows 18.53% growth. Joel Greenblatt would examine position.
-0.97%
Other expenses reduction while VET shows 50.36% growth. Joel Greenblatt would examine advantage.
-91.09%
Pre-tax income decline while VET shows 132.74% growth. Joel Greenblatt would examine position.
-75.90%
Pre-tax margin decline while VET shows 128.86% growth. Joel Greenblatt would examine position.
17.07%
Tax expense growth less than half of VET's 119.42%. David Dodd would verify if advantage is sustainable.
-165.00%
Net income decline while VET shows 181.64% growth. Joel Greenblatt would examine position.
-143.93%
Net margin decline while VET shows 171.96% growth. Joel Greenblatt would examine position.
-165.22%
EPS decline while VET shows 227.27% growth. Joel Greenblatt would examine position.
-177.27%
Diluted EPS decline while VET shows 227.27% growth. Joel Greenblatt would examine position.
-1.59%
Both companies reducing share counts. Martin Whitman would check patterns.
0.04%
Diluted share increase while VET reduces shares. John Neff would investigate differences.